药物基因组学用药指导服务费
其他
≈ ¥800-2500
(≈ $115-360)
大约3-7个工作日出报告
免责声明：本站为医疗服务机构，页面信息部分由AI协助制作。健康相关信息不构成医疗建议。如有任何疑问，请咨询医疗专业人士。详情见免责声明
项目介绍
药物基因组学用药指导服务费在一般公立医院参考费用约¥560-2000，三甲医院参考费用约¥800-2500，常用于相关诊断评估与就医安排，费用随医院及地区有所差异。
主要用途
Pharmacogenomic medication guidance service supports precision prescribing by identifying genetic variants affecting drug metabolism, transport, or targets. Primary uses include: optimizing drug selection (e.g., avoiding clopidogrel in CYP2C19 poor metabolizers); individualizing dosing (e.g., warfarin dosing guided by VKORC1/CYP2C9); predicting risk of adverse drug reactions (e.g., HLA-B*15:02-associated carbamazepine-induced SJS/TEN); informing therapeutic switching (e.g., SSRIs based on CYP2D6/CYP2C19 status); and supporting clinical decision-making in psychiatry, cardiology, oncology, and pain management per evidence-based guidelines (CPIC, FDA PGx biomarker labels).
正常值范围
Not applicable — Pharmacogenomic testing is qualitative or semi-quantitative; it does not yield numerical 'values' with a universal normal range. Instead, results are reported as genotype/allele calls (e.g., CYP2C19*1/*2), predicted phenotype (e.g., Poor Metabolizer, Normal Metabolizer), or clinical interpretation (e.g., 'Use alternative drug' or 'Reduce dose'). Reference standards depend on the specific gene-drug pair (e.g., CYP2C19 for clopidogrel; SLCO1B1 for simvastatin) and are defined by CPIC (Clinical Pharmacogenetics Implementation Consortium) or DPWG (Dutch Pharmacogenetics Working Group) guidelines.
偏低可能原因
N/A — 'Low value' is a misnomer for pharmacogenomic testing, as it does not measure analyte concentration. Apparent 'low' interpretations (e.g., reduced enzyme activity) stem from genetic variants: 1) Presence of loss-of-function alleles (e.g., CYP2C19*2 or *3); 2) Homozygous or compound heterozygous variant genotypes; 3) Gene deletions or copy number variants (e.g., CYP2D6 deletion); 4) Rare promoter variants reducing transcription; 5) Technical limitations (e.g., poor DNA quality or assay failure leading to inconclusive/missing calls).
偏高可能原因
N/A — 'High value' is not applicable in standard pharmacogenomic reporting. Increased functional activity is inferred from genotypes: 1) Presence of gain-of-function alleles (e.g., CYP2D6*1xN or *2xN duplications); 2) Ultrarapid metabolizer genotype (e.g., CYP2D6 gene duplication + functional alleles); 3) Wild-type homozygous genotype (*1/*1) for genes where *1 denotes full function; 4) Absence of known loss-of-function variants; 5) Technical artifacts (e.g., allele dropout in one primer site causing false homozygous wild-type call).